MapLight Therapeutics
2 clinical trials · 2 recruiting · INDUSTRY
Trials by MapLight Therapeutics
RECRUITINGPhase 2NCT06887192
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90...
Sponsor: MapLight TherapeuticsEnrolling: 30020 locations
Psychosis Associated With Alzheimer's Disease
RECRUITINGPhase 2NCT07038876
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient...
Sponsor: MapLight TherapeuticsEnrolling: 30020 locations
Schizophrenia